Pembrolizumab shows promise in treatment of mesothelioma

March 20, 2017, Perelman School of Medicine at the University of Pennsylvania

Pembrolizumab, an antibody drug already used to treat other forms of cancer, can be effective in the treatment of the most common form of mesothelioma, according to a new study led by investigators from the Perelman School of Medicine at the University of Pennsylvania. The study, published this month in The Lancet Oncology, is the first to show a positive impact from checkpoint inhibitor immunotherapy drugs on this disease.

Malignant pleural mesothelioma is a rare and aggressive cancer that represents about 90 percent of all malignant mesothelioma cases. It's primarily caused by the inhalation of asbestos, a fiber commonly found in some forms of insulation, vinyl floor tiles, and other material. Tumors form in the pleura, a thin membrane of cells that line the lungs and chest wall. Most survive less than a year. This poor prognosis is partially due to the fact that most patients are not diagnosed until they are already at a late stage of the disease. The standard first-line therapy treatment involves chemotherapy, and currently there is no approved second-line therapy.

"There have been a lot of studies looking at different drugs, but researchers have not seen positive results," said the study's lead author Evan Alley, MD, PhD, chief of Hematology and Medical Oncology at Penn Presbyterian Hospital. "But we've found this new class of drugs, checkpoint inhibitors, seems to be more effective than what's been available in the past."

Checkpoint inhibitors are a class of drugs designed to free the body's immune system to fight back against cancer. Pembrolizumab, in particular, has been used to treat melanoma, non-small cell lung cancer, and in some cases, head and neck cancers.

Alley and his team presented data from KEYNOTE-028, an ongoing trial involving 13 different research sites in six different countries all looking at the effect of pembrolizumab on patients with advanced malignancies, including . The study evaluated 25 patients with pleural mesothelioma, all of whom were over the age of 18 and had either already been treated with chemotherapy or were unable to receive it. Patients who had already received another checkpoint inhibitor were not included in the study.

Beginning with the first enrollees two years ago, doctors gave each patient a dose of pembrolizumab every two weeks. The tumor reduced in size in 14 of those patients. On average, patients went about six months without their disease progressing, and overall survival was about 18 months. Fourteen patients passed away during the study, while four were still undergoing treatment as of the study's writing.

"Most patients who receive a second-line therapy have a life expectancy of about six or seven months, so to have four patients still ongoing at two years is very encouraging," Alley said.

The most common side-effects reported were fatigue, nausea, loss of appetite, and dry mouth.

"One great sign in this study is that none of the patients had to stop treatment because of side-effects," Alley said. "Some had temporary stoppages, but they were able to continue. The appears to be well-tolerated."

There are multiple studies going on right now to confirm these findings, which the authors note is a necessary step before the drug can become a standard second-line therapy. "This study provides evidence that some patients can have long-term disease control with this drug, which we haven't seen before," Alley said. "We need to better understand what we can do next to make immunotherapy more effective for more patients."

Alley said there are already plans for trials that will test combination therapies, which will utilize pembrolizumab in conjunction with other treatments. Those studies are expected to launch later this year, including two at Penn.

Explore further: Immunotherapy drug pembrolizumab shows promise for mesothelioma patients

More information: Evan W Alley et al, Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial, The Lancet Oncology (2017). DOI: 10.1016/S1470-2045(17)30169-9

Related Stories

Immunotherapy drug pembrolizumab shows promise for mesothelioma patients

April 20, 2015
The PD-1 inhibitor pembrolizumab, a cancer immunotherapy drug, shrank or halted growth of tumors in 76 percent of patients with pleural mesothelioma, a rare and deadly form of cancer that arises in the outer lining of the ...

Study of potential new treatment for mesothelioma open to patients

September 15, 2016
The Baylor College of Medicine Mesothelioma Treatment Center at Baylor St. Luke's Medical Center has begun enrolling patients in a clinical research study looking at an investigational drug in patients with malignant pleural ...

The immunotherapy, pembrolizumab, is active against mucosal melanoma tumors

January 29, 2017
Clinical trials of a new immunotherapy, pembrolizumab, have shown that it prolongs life significantly for patients with bladder cancer and is active against a rare sub-type of melanoma, called mucosal melanoma. The findings ...

Combination of radiation and immune checkpoint therapy holds potential for lung cancer

March 16, 2017
An emerging approach for cancer treatment seeks to combine radiation therapy with immune checkpoint inhibitors (ICPIs) to more effectively control tumors in the chest with an acceptable risk of severe treatment-related side ...

Pembrolizumab elicits significant antitumor activity in head and neck cancer patients

June 6, 2016
Treating head and neck cancer patients with recurrent or metastatic disease with the PD-1 inhibitor pembrolizumab resulted in significant clinical responses in a fifth of the patients from a phase II clinical trial, researchers ...

ASCO: Pembrolizumab is good second-line Tx in urothelial CA

February 21, 2017
(HealthDay)—For patients with advanced urothelial cancer that has recurred or progressed after platinum-based chemotherapy, pembrolizumab is associated with increased overall survival, according to a study published online ...

Recommended for you

Researchers use a molecular Trojan horse to deliver chemotherapeutic drug to cancer cells

February 23, 2018
A research team at the University of California, Riverside has discovered a way for chemotherapy drug paclitaxel to target migrating, or circulating, cancer cells, which are responsible for the development of tumor metastases.

An under-the-radar immune cell shows potential in fight against cancer

February 23, 2018
One of the rarest of immune cells, unknown to scientists a decade ago, might prove to be a potent weapon in stopping cancer from spreading in the body, according to new research from the University of British Columbia.

Lab-grown 'mini tumours' could personalise cancer treatment

February 23, 2018
Testing cancer drugs on miniature replicas of a patient's tumour could help doctors tailor treatment, according to new research.

Study tracks evolutionary transition to destructive cancer

February 23, 2018
Evolution describes how all living forms cope with challenges in their environment, as they struggle to persevere against formidable odds. Mutation and selective pressure—cornerstones of Darwin's theory—are the means ...

Putting black skin cancer to sleep—for good

February 22, 2018
An international research team has succeeded in stopping the growth of malignant melanoma by reactivating a protective mechanism that prevents tumor cells from dividing. The team used chemical agents to block the enzymes ...

Cancer risk associated with key epigenetic changes occurring through normal aging process

February 22, 2018
Some scientists have hypothesized that tumor-promoting changes in cells during cancer development—particularly an epigenetic change involving DNA methylation—arise from rogue cells escaping a natural cell deterioration ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.